Company ProfilePremium

Ju Fu Tang Biotech Holdings Co., Ltd

Company Profile Analysis

Ticker: 8217.HK

ESOMAR 23 Corporate BadgeISO Certifications Badge
Ju Fu Tang Biotech Holdings Co., Ltd - Company showcase

Year Founded & Workforce

2015

23 Employees

Ju Fu Tang Biotech Holdings Co., Ltd logo

Ju Fu Tang Biotech Holdings Co., Ltd Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Ju Fu Tang Biotech Holdings Co., Ltd Overview

Ju Fu Tang Biotech is a Hong Kong micro-cap in transition. Its revenue base is still almost entirely a small civil engineering and fit-out subcontracting business, now overlaid with an investment portfolio and an embryonic medical-device trading arm. In FY2026, 94% of revenue (HK$35.4M) came from roads and drainage, structural works, site formation and decoration subcontracting for a highly concentrated client base. One customer contributed 85% of revenue. A new "health technology" segment sold HK$2.1M of medical devices through a newly formed Shenzhen subsidiary. The return to a reported profit of HK$23.3M was driven by HK$27.4M of fair-value gains on Hong Kong-listed equities, not by operations. Operating margins in construction remain near break-even. The 2025 rebranding to a "biotech" name signals management's intent to pivot towards wellness, elderly-care and medical technology serving the Greater Bay Area. That strategy is, however, at an early stage and is not yet resourced at scale.


Company's own description (paraphrased from the FY2026 Annual Report)

The Group describes itself as engaged in three activities: (1) civil engineering and construction; (2) health technology and medical-product sales; and (3) investment holding. The Company itself is an investment holding company.

The ESG report states that, despite the English name change during the year, the Group's principal business remains that of a civil engineering subcontractor in Hong Kong. Its civil works fall into four categories:

Roads and drainage: building and improving local roads, carriageways with junction improvements and associated footpaths, planting areas, drains, sewers, water mains and utility diversions.

Structural works: reinforced concrete structures, including bridges and retaining walls.

Site formation: excavation and/or filling to form new sites or reach designed formation levels.

Decoration and renovation: fit-out works including carpentry, marble, plastering, ceiling installation and project-management support.

The health technology business sells medical-device products. Revenue is recognised at the point the customer accepts delivery. Management concluded that the Group acts as principal in these sales because it controls inventory before transfer and bears inventory risk.

Business model and revenue model

DimensionCharacterisationEvidence
Revenue model mixProject or contract services (94.4% of FY2026 revenue) plus product sales (5.6%). There is no subscription or licensing revenue.FY2026 AR note 8
PricingConstruction work is priced cost-plus at tender. Mark-ups are lower on larger contracts and adjusted for complexity, uncertainty and competition. Contracts have fixed prices with milestone payments.FY2026 AR MD&A, note 8
RetentionClients typically withhold 5–10% of contract value as retention for 1–2 years. This sits in contract assets until the defects period ends.FY2026 AR note 20
RecognitionConstruction revenue is recognised over time using an output method based on surveys and interim payment applications. Medical-device revenue is recognised at a point in time.FY2026 AR note 3
Value-chain positionTier-2/3 subcontractor beneath main contractors. Construction waste is handled by the main contractor. Heavy reliance on sub-subcontractors: the largest subcontractor took 58% of subcontracting spend and the top five took 99%.FY2026 AR ESG and Directors' Report
Customer typesMain contractors on public and private civil works in Hong Kong. The top five customers have mostly worked with the Group for more than 10 years. Medical-device customers are in the PRC (names not disclosed).FY2026 AR
End-marketsHong Kong public infrastructure and private development (civil); PRC medical-device distribution (health technology); Hong Kong-listed equities (investment).FY2026 AR

Independent characterisation

In economic terms, the Group is three things:

  1. A sub-scale, low-margin construction subcontractor. Gross margin was 2.7% in both FY2025 and FY2026.

  2. A concentrated small-cap equity portfolio. HK$51.4M at 31 March 2026, equal to 55.5% of total assets and more than the Group's entire equity. Its mark-to-market swings now drive reported earnings.

  3. An optional pivot into health and wellness. The "Ju Fu Tang" (菊福堂) brand and the health-care (康養) business led by general manager Mr. Cai Chunzhi (蔡淳治) were cited as reasons for the 2025 name change. So far this has produced HK$2.1M of medical-device revenue and a segment loss of HK$19k.

The investment case is therefore driven by net asset value and catalysts rather than by earnings power.

Strategy

Stated strategy (paraphrased themes from the FY2026 Chairman's Statement)

  1. Dual-engine strategy. Build a more resilient, diversified group by combining a stabilised construction division with a growing health technology and medical-device sales business.

  2. Construction: target resilient public-sector demand. Management cites the HK Government's 2026–27 Budget, which projects average annual capital works spending of about HK$120bn over the five years to 2030–31 and recurrent spending growth of about 3.6% per year. It intends to widen participation in public-sector work and pursue workforce certifications to win higher-value contracts.

  3. Health technology: ride policy-led precision medicine. Management cites the "Healthy China 2030" and 15th Five-Year Plan frameworks and an estimated US$17–19bn domestic AI-healthcare market by 2030. It plans to:

    • embed AI solutions in clinical workflows;

    • use Hong Kong's forthcoming medicines regulator, the "1+" approval mechanism and the Drug and Device Connect scheme to speed up cross-border registrations;

    • use the Hetao (Loop) cooperation zone and Greater Bay Area partnerships to move medical technologies from research to clinical use.

  4. Opportunistic diversification. Management says it will continue to seek new business opportunities to diversify revenue and improve market position.

  5. Investment portfolio. Maintain a diversified, flexible portfolio aimed at long-term returns while keeping the core business stable.

Initiatives announced in the last 24 months

DateInitiativeDetail / status
10 Jun 2025Rebrand to Ju Fu Tang BiotechRationale: new corporate identity to support the health-care (康養) business under GM Mr. Cai Chunzhi and broaden revenue. Completed 11 Sep 2025.
8 Sep 20252025 Share Option Scheme10-year scheme. Mandate of 30,186,000 shares (10%). No options granted under it to date.
FY2026Incorporation of Anjulai Biotechnology (Shenzhen)Registered capital US$200k, unpaid at year end. Generated HK$2.11M of revenue.
FY2026Incorporation of Right Estate Limited (BVI)Investment holding vehicle.
FY2026Disposal of owned officeHK$2.92M proceeds and HK$2.80M gain. Reduces fixed assets to nil.
FY2026Cost programmeStaff costs cut 40% (HK$5.06M to HK$3.03M); admin costs down 8.8%. No formal target disclosed.
FY2026Climate disclosureAdopted HKEX climate framework (IFRS S2-based). Target to maintain or reduce Scope 1+2 and energy intensity over the next three fiscal years from the FY2026 baseline.

Medium-term targets and guidance

The company provides no revenue, margin or return targets, and no quantitative guidance. The only quantitative forward-looking disclosures are the ESG intensity targets and the HK$32.8M of remaining performance obligations expected to be recognised within one year.

Products & Services

The Group does not disclose brand names, SKUs, product specifications or price lists for any offering. The catalogue below is built from filing descriptions.

Civil engineering, decoration & renovation segment

OfferingDescription / capabilitiesTarget customerLaunch / statusPricing model
Roads and drainage worksConstruction and improvement of local roads, carriageways and junctions, footpaths, planting areas, drains, sewers, water mains, utility diversionMain contractors on public works (e.g. government projects) and private developmentsCore legacy service (25+ years)Fixed-price contracts tendered cost-plus, milestone billing, 5–10% retention
Structural worksReinforced concrete structures including bridges and retaining wallsMain contractorsCore legacy serviceSame
Site formation worksExcavation and/or filling to form new sites or achieve design levelsMain contractors and developersCore legacy serviceSame
Decoration and renovation worksInterior fit-out: carpentry, marble, plastering, ceiling installation, project-management supportMain contractors and building ownersExpanded in recent years via 穆倫建業Same
Maintenance servicesMaintenance related to completed worksExisting clientsOngoing—

Order book: 13 contracts on hand with total contract value of HK$394.23M at 31 Mar 2026 (12 contracts, HK$346.89M, at 31 Mar 2025). Transaction price allocated to unsatisfied obligations and expected to be recognised within one year was HK$32.8M (HK$31.3M prior year) (FY2026 AR MD&A and note 8). The gap between total contract value and remaining performance obligations suggests most listed contracts are substantially complete.

Health technology segment

OfferingDescriptionTarget customerLaunchPricing
Medical-device product salesWholesale and trading of medical-device products via Anjulai Biotechnology (Shenzhen). Specific devices are not publicly disclosed. Warranty is assurance-type, with returns limited to quality defects.PRC customers (not named)FY2026Per-order sale; principal accounting
Health care / wellness (康養) businessCited in the June 2025 name-change rationale as led by GM Mr. Cai Chunzhi. No separate revenue disclosed.—In development—
AI-enabled clinical solutions and cross-border registration (stated ambition)The Chairman's Statement describes intentions to embed AI solutions into clinical workflows, use Hong Kong's new regulatory channels (planned HK medicines regulator, "1+" approval mechanism, Drug and Device Connect) for faster cross-border registration, and build Greater Bay Area partnerships.—Aspirational; no product launched—

Investment holding activities

Holding (HK-listed)Shares heldStakeCost (HKD K)Fair value 1 Apr 2025 (HKD K)Fair value 31 Mar 2026 (HKD K)FY2026 gain/(loss) (HKD K)% of total assets
滙隆控股有限公司 (GEM; scaffolding and fitting-out)381,660,0002.66%9,76214,8853,817(11,068)4.1%
亞洲策略數字科技控股有限公司 (Main Board; umbrella manufacturing)9,100,0002.21%1,8208,28127,84619,56530.1%
Tam Kam Holdings Limited (GEM)7,212,0001.34%8,5351,87510,2418,36611.1%
Nine other HK-listed equities (each below 5% of total assets)———3,0189,473—10.2%
Total———28,05951,377—55.5%

Source: FY2026 AR MD&A.

The investment policy permits shares, bonds, funds, insurance products and deposits. It prohibits excessive leverage, unlisted securities and speculative derivatives. The two executive directors can approve single investments below 5% of market capitalisation or total assets; larger investments require board approval.

Financial Narrative

Sources and conventions. FY2026 and FY2025 figures are from the FY2026 audited financial statements. Revenue, profit before tax, net result, total assets, total liabilities and net assets for FY2022–FY2024 are from the FY2026 AR five-year summary.

Income statement

FY2022 EPS uses the weighted average of 200.74M shares (rights issue year). FY2023–FY2024 EPS is computed on 301.86M shares. FY2025–FY2026 EPS is as reported.

Margins

Revenue CAGR: FY2022–FY2026 (4 years) is approximately -20.2% per year. From the FY2017 peak (HK$735M, aggregator) to FY2026, revenue has fallen roughly 95%.

Commentary on the income statement. Reported earnings are almost entirely non-operating. Of the HK$24.0M operating profit in FY2026, HK$27.4M came from unrealised and realised fair-value gains on listed equities and HK$2.8M from selling the office property. A net HK$1.3M came from expected credit loss reversals: HK$7.2M of contract-asset recoveries, offset by a HK$6.0M trade-receivable impairment, of which HK$21.0M (gross) relates to a customer more than two years overdue.

Underlying construction economics remain marginal. Gross profit of HK$1.0M against administrative costs of HK$8.5M implies a core operating loss of about HK$7.5M before investment gains.

Administrative costs fell 8.8%, helped by lower staff costs (HK$3.0M versus HK$5.1M), lower marketing and lower severance. Professional fees rose to HK$1.25M (HK$0.50M prior year) and marketing expenses to HK$1.45M (HK$0.83M), consistent with the rebranding.

Other income fell from HK$1.39M to HK$12k because FY2025 included a HK$520k work-injury insurance recovery, HK$194k of government subsidy and a HK$648k long-service-payment over-provision reversal.

The inflection in FY2024 is notable. Revenue collapsed 66% as major projects completed. Management notes that revenue from its main customer fell about 36% between FY2023 and FY2026, in line with the broader Hong Kong construction market.

Balance sheet

FY2022 and FY2023 bond balances assume the HK$12M bond (drawn December 2020) remained outstanding. FY2024 cash is the opening cash balance for FY2025 per the cash flow statement.

FY2026 versus FY2025 detail (HK$k, FY2026 AR):

At company level, distributable reserves were nil at 31 March 2026, and the Company had an accumulated loss of HK$103.3M (note 31).

Cash flow

FY2026 operating cash flow was helped by HK$12.5M of contract-asset unwinding and HK$8.2M of receivable collections. Investing inflows comprise HK$5.76M of securities disposals, less HK$1.68M of purchases, plus HK$2.92M of property proceeds. Financing outflows were a HK$5.38M repayment to a subsidiary director and HK$2.26M to a former shareholder.

Ratios

Notes on the ratios:

  • ROE and ROA use average balances, except FY2022, which uses closing balances.

  • ROIC is operating profit divided by (equity plus bonds), with no tax because of tax losses.

  • Debt to equity counts only the HK$12M bond. The FY2025 and FY2026 figures match the reported gearing of 44% and 24%.

  • There is no inventory, so the cash conversion cycle equals DSO minus DPO.

  • Net debt to EBITDA is not meaningful for loss-making years.

Trend commentary. The balance sheet improved sharply in FY2026. Equity rose 86% to HK$50.5M and net debt fell to HK$2.7M. However, the quality of that improvement is weak.

First, 55% of assets are listed small-cap equities, two of which have extreme price histories. The 滙隆 stake lost 74% of its value in the year, while the 亞洲策略 stake rose more than threefold.

Second, the HK$12M 6% bond has been overdue since 2 December 2022 and accrued interest payable has reached HK$3.7M. The filings classify it as current and do not describe it as a default event. However, it represents a creditor claim of roughly HK$15.7M including interest, against only HK$9.3M of cash.

Third, credit quality in the receivable book is poor. The average expected loss rate on trade receivables is 64% (HK$21.1M of allowance on HK$33.0M gross).

Unrecognised tax losses of HK$81.0M (HK$98.8M prior year) provide a tax shield for future profits.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Segment revenue (HKD K)

Segment revenue (HKD K)FY2024FY2025FY2026

Civil engineering, decoration & renovation

35,14136,20235,441

Health technology (medical devices)

002,114

Total revenue

35,14136,20237,555

Segment Revenue

Metric (FY2026)Civil engineering, decoration & renovationHealth technologyTotal / unallocated

Segment revenue (HKD K)

35,4412,11437,555

Cost of sales (HKD K)

(34,466)(2,072)(36,538)

Segment gross margin

2.75%1.99%2.71%

Trade receivable impairment (HKD K)

(5,902)(55)(5,957)

Contract asset impairment reversal (HKD K)

7,201—7,201

Segment profit/(loss) (HKD K)

437(19)418

Segment profit margin

1.2%

(0.9%)

1.1%

YoY revenue growth

(2.1%)

n/m (new)

+3.7%

Share of revenue

94.4%5.6%100%

Segment assets (HKD K)

32,3422,407

57,861 unallocated (mainly FVTPL)

Segment liabilities (HKD K)

21,9192,427

17,729 unallocated

Segment margin (%)

Segment margin (%)FY2024FY2025FY2026

Civil engineering gross margin (%)

5.352.712.75

Health technology gross margin (%)

——1.99

Group Entities

SubsidiaryPlace of incorporation / operationIssued capitalGroup interestPrincipal activity

Right Estate Limited

BVI

5 shares of US$1

100% (direct; incorporated FY2026)

Investment holding

—

Hong Kong

9,280,000 ordinary shares

100%

Civil engineering works

—

Hong Kong

10,000 ordinary shares

100% (direct)

Decoration and renovation works

Anjulai Biotechnology (Shenzhen) Company Limited (English name for identification only)

PRC

Registered US$200,000; paid-up nil

100% (incorporated FY2026)

Wholesale and sale of medical-device products

Income Statement and Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

Revenue (HKD K)

92,754104,60135,14136,20237,555

Revenue growth YoY (%)

-44.912.8-66.43.03.7

Gross profit (HKD K)

1,040-2,8801,8809821,017

Operating income (HKD K)

-19,480-9,240-16,710-5,17924,038

EBITDA (HKD K)

-19,140-9,130-16,630-5,09924,078

Finance costs (HKD K)

733721720720720

Pre-tax income (HKD K)

-20,208-9,963-17,433-5,89923,318

Net income attributable (HKD K)

-20,147-9,963-17,433-5,89923,318

EPS basic (HK cents)

-10.04-3.30-5.78-1.957.72

EPS diluted (HK cents)

-10.04-3.30-5.78-1.957.62

Dividend per share (HK cents)

00000

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

Gross margin (%)

1.12-2.755.352.712.71

Operating margin (%)

-21.00-8.83-47.55-14.3164.01

EBITDA margin (%)

-20.64-8.73-47.32-14.0864.11

Net margin (%)

-21.72-9.52-49.61-16.2962.09

Financial Analysis

ItemFY2025FY2026

Revenue

36,20237,555

Cost of services

(35,220)(36,538)

Gross profit

9821,017

Other income

1,39212

Other net gains (FVTPL change; property disposal)

5,349

30,190 (27,391 FVTPL + 2,799 disposal)

Expected credit loss (charge)/reversal, net

(3,549)1,345

Administrative and other operating expenses

(9,353)(8,526)

Operating profit/(loss)

(5,179)24,038

Finance costs

(720)(720)

Profit/(loss) before tax

(5,899)23,318

Profit/(loss) for the year

(5,899)23,318

Balance Sheet

MetricFY2022FY2023FY2024FY2025FY2026

Total assets (HKD K)

144,347105,51481,55480,36592,610

Total liabilities (HKD K)

83,83454,96448,43753,14742,075

Total equity (HKD K)

60,51350,55033,11727,21850,535

Cash and bank balances (HKD K)

——4,0052,1139,276

FVTPL listed equities (HKD K)

———28,05951,377

Short-term debt — bonds payable (HKD K)

12,00012,00012,00012,00012,000

Long-term debt (HKD K)

———00

Net debt (HKD K)

——7,9959,8872,724

Goodwill and intangibles (HKD K)

———00

Working capital — net current assets (HKD K)

———27,05550,535

Margin Analysis (%) (31 Mar 2025–31 Mar 2026)

Line item31 Mar 202531 Mar 2026

Property, plant and equipment

163—

Contract assets (net of ECL 2,201 / 9,402)

13,5588,250

Contract costs

2,221978

Trade and other receivables

34,25120,520

— of which trade receivables, net (gross 32,978; ECL 21,099)

26,06511,879

— of which receivable from securities broker

9074,475

— of which performance bond deposits

7,2154,107

Amount due from a related party (net)

—2,209

FVTPL financial assets

28,05951,377

Cash and bank balances

2,1139,276

Current assets

80,202

92,610

Contract liabilities

1,517274

Trade and other payables (incl. retention payable 13,778; interest payable 3,737)

36,73929,174

Amount due to a former shareholder

2,264—

Bonds payable (6%, matured 2 Dec 2022)

12,00012,000

Tax payable

627627

Current liabilities

53,147

42,075

Net assets

27,218

50,535

Share capital

48,29848,298

Reserves

(21,080)2,237

Cash Flow

MetricFY2022FY2023FY2024FY2025FY2026

Operating cash flow (HKD K)

———-7,2707,810

Capex (HKD K)

———00

Free cash flow (HKD K)

———-7,2707,810

Investing cash flow (HKD K)

———06,995

Financing cash flow (HKD K)

———5,378-7,642

Dividends paid (HKD K)

00000

Share buybacks (HKD K)

00000

Returns & Leverage Ratios (%) and Financial Ratios (x)

MetricFY2022FY2023FY2024FY2025FY2026

ROE (%)

-33.3-17.9-41.7-19.660.0

ROA (%)

-14.0-8.0-18.6-7.327.0

ROIC (%)

———-13.238.4

Current ratio (x)

———1.52.2

Debt to equity (%)

19.823.736.244.123.7

Net debt to equity (%)

——24.136.35.4

Net debt to EBITDA (x)

——-0.48-1.940.11

Interest coverage (x)

-26.6-12.8-23.2-7.233.4

Asset turnover (x)

0.640.840.380.450.43

DSO, trade receivables (days)

———263115

DPO, trade payables (days)

———12192

Cash conversion cycle (days)

———14223

Region revenue (HKD K)

Region revenue (HKD K)FY2024FY2025FY2026

Hong Kong

35,14136,20235,441

PRC (Mainland China)

002,114

Total

35,14136,20237,555

Region growth YoY (%)

Region growth YoY (%)FY2025FY2026

Hong Kong

3.0-2.1

Share Price History

DatePrice (HKD)Source

15 May 2026

0.243 (real-time quote)

etnet

Early Jul 2026

0.106–0.113

Lixinger / etnet

22 Sep 2026

0.09 (-10% on day)

GrowthInvesting

Performance metric

Value

Source / note

3-year price change

About -28.6%

GrowthInvesting

Annualised return since listing

About -45.9% per year

Lixinger (early Jul 2026)

Board lot

10,000 shares

Lixinger; 2021 announcement

Liquidity

Very thin; HK$161k turnover on a sample day (0.5% turnover)

Lixinger

Valuation Snapshot

MultipleValueCalculation

Market capitalisation

HK$27.2M

301.86M shares × HK$0.09

Enterprise value

HK$29.9M

Market cap + HK$12.0M bond − HK$9.3M cash

EV excluding listed securities

About -HK$21.5M

EV − HK$51.4M FVTPL assets

P/E (trailing, reported)

1.2x

0.09 / 0.0772

P/E excluding fair-value and disposal gains

Not meaningful (core loss)

—

EV/EBITDA

1.2x

29.9 / 24.1

EV/Sales

0.80x

29.9 / 37.6

P/B

0.54x

27.2 / 50.5

Lixinger quoted (early Jul 2026, price 0.106)

P/E 1.37x, P/B 0.63x; HK heavy-infrastructure sub-sector P/E 4.82x, P/B 0.27x

Lixinger

Capital Markets

ItemDetail

Analyst consensus

No sell-side coverage; no price targets

Dividend history

No dividends paid in FY2022–FY2026. Distributable reserves at company level are nil.

Dividend policy

Adopted March 2019; discretionary, based on performance, cash, reserves and outlook

Buybacks

None since listing. A repurchase mandate (up to 10%) was proposed at the 2026 AGM.

Credit ratings

None (Moody's, S&P and Fitch do not rate the company)

Share options outstanding

19,842,480 (6.6% of issued shares): 10,698,480 at HK$0.315 (5-year term from 12 Jul 2021, now expired or expiring) and 9,144,000 at HK$0.163 (expire around 18 Mar 2027). Weighted average exercise price HK$0.245.

Capital Instruments

InstrumentPrincipalRateMaturityStatus

Unsecured bonds

HK$12.0M

6%

2 Dec 2022

Overdue; repayable on demand. Undiscounted cash flow HK$12.72M within one year.

Bank facilities

———

No general banking facilities

Analyst Conclusions

Management guidance and consensus

Management provides no quantitative guidance. Qualitatively, it expects to:

  • pursue broader construction opportunities, especially in the public sector;

  • seek workforce certifications to win higher-value contracts;

  • develop the health technology and medical-device business under the dual-engine strategy.

There are no consensus forecasts. The near-term revenue floor is HK$32.8M of remaining performance obligations expected within one year (FY2026 AR note 8). The next scheduled catalyst is interim results for the six months to 30 September 2026, expected around late November 2026.

Bull case

  1. Asset backing. Listed securities of HK$51.4M plus cash of HK$9.3M total HK$60.7M, more than twice the market capitalisation of about HK$27M. Even after the HK$15.7M bond and accrued interest, net liquid assets of about HK$45M exceed the market value.

  2. Order book. Construction backlog of HK$394.2M across 13 contracts, with HK$32.8M due within one year, underpins about HK$35M of stable revenue. The HK$120bn-a-year government capital works programme supports tender opportunities.

  3. Pivot upside with low fixed costs. The asset-light structure (no PPE, 23 staff, admin costs falling 8.8%) and HK$81M of tax losses mean that any scalable health-tech revenue could flow through at high incremental margins.

Bear case

  1. Earnings are portfolio marks. The FY2026 profit is wholly attributable to HK$27.4M of fair-value gains. 30% of total assets sits in one Main Board micro-cap (亞洲策略) whose investee recorded a pre-tax loss of RMB8.4M on RMB276.5M revenue. A reversal could erase most of the equity gain.

  2. Structural decline in the core business. Revenue has fallen about 95% from its FY2017 peak. Gross margin is 2.7% and customer concentration is 85%. The core business lost about HK$7.5M before investment gains in FY2026, and receivables carry a 64% loss allowance.

  3. Credit, governance and dilution overhangs. The bond has been overdue since 2022. There is no internal audit, related-party asset sales, an auditor change over fees, a 2021 rights issue, and fresh issue and option mandates. A fragmented shareholder base with no controlling shareholder raises the risk of further dilutive capital raises to fund the "biotech" strategy.

Catalysts and monitorables (next 12 months)

MonitorableWhy it mattersTiming
Interim results (H1 FY2027)Mark-to-market on the portfolio; core construction margin; health-tech scaleAround late Nov 2026
Bond resolution (repayment, extension or enforcement)Removes or crystallises the principal credit overhangAny time
Customer A contract renewals and new tenders85% revenue dependencyOngoing
Health-tech disclosures (products, approvals, partners, capital injection into the Shenzhen subsidiary)Tests credibility of the rebrandOngoing
Portfolio actions (disposals of 亞洲策略 and Tam Kam stakes)Crystallising gains would validate NAVOngoing
Equity issuance under the 20% general mandate or option grantsDilution riskPost-AGM (10 Sep 2026)
HK$3.0M flooding litigationContingent liabilityOngoing
Option expiry (9.144M at HK$0.163)Minor overhang removalAround Mar 2027
Board and committee reconstitution (nomination chair after Liao)Governance qualityNear term

Analyst verdict

Ju Fu Tang Biotech is best understood as a listed shell-like holding company with three loosely related assets: a shrinking construction subcontractor, a volatile small-cap equity book, and an unproven health-technology option. The FY2026 headline swing from a HK$5.9M loss to a HK$23.3M profit is real in accounting terms but not operational. Fair-value gains of HK$27.4M exceeded total net profit, while the construction division made HK$437k of segment profit on HK$35.4M of revenue, and the new medical-device unit lost HK$19k.

The balance sheet is genuinely stronger. Equity has nearly doubled to HK$50.5M, net debt is HK$2.7M and the current ratio is 2.2x. Yet the composition of that equity is fragile. More than half of all assets are three Hong Kong micro-cap positions, one of which lost three-quarters of its value in the same year another tripled.

The market is pricing these risks aggressively. At HK$0.09, the stock trades at about 0.54x book and well below the value of its listed securities alone. That discount is rational given the long-overdue HK$12M bond, extreme customer concentration, poor receivable recoverability, related-party dealings, no internal audit and a history of dilutive capital raising.

The rebrand to a "biotech" identity is, at present, a statement of intent rather than an operating reality. There is no R&D, no IP, no disclosed product pipeline, and the Shenzhen subsidiary's registered capital is unpaid. For deep-value or special-situation investors, the asset discount offers asymmetric upside if management crystallises portfolio gains, retires the bond and demonstrates credible health-tech traction. For most institutional mandates, liquidity, governance and earnings-quality issues make the shares uninvestable.

Overall assessment: speculative, NAV-driven situation. Monitor the November 2026 interims, bond resolution and any capital-raising before taking any view beyond a watch-list position.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameRoleAgeAppointedBackground and educationFY2026 total emoluments (HKD K)

Mr. Chen Jian (陳健)

Executive director; compliance officer; authorised representative; signs the Chairman's Statement

62—

30+ years of corporate management experience in Hong Kong and the PRC. Responsible for business development and general administration. No other listed directorships in the past three years.

120 (fees only)

Ms. Yu Xiao (余曉)

Executive director; remuneration committee member

45

16 Nov 2017

10+ years in civil engineering and real estate construction. Formerly architect and civil engineering department engineer at 湖南和慶源建設工程有限公司. BEng in civil engineering, Hunan University (June 2000).

120

Mr. Wong Chi Kan (黃智瑾)

INED; chair of audit and remuneration committees

40

12 Apr 2016

Finance director at a private company since June 2017. Previously assistant finance director at a financial PR firm and accounting manager at a GEM-listed packaging company, plus several accounting firms. BCom (2009) and Master of Professional Accounting (2010), University of New South Wales. FCPA (CPA Australia, since March 2014). HKICPA practising accountant.

120

Ms. Lao In Iam (劉燕欽)

INED; audit and nomination committee member

53

18 Aug 2020

20+ years in construction, including overall management and supervision of large projects in Macau.

96

Ms.

INED; audit, remuneration and nomination committee member

55

17 Aug 2026

20+ years in corporate governance, internal control review, pre-listing compliance, risk oversight and fraud prevention. MBA, Chinese University of Hong Kong. BA (Hons) Accounting and Finance, University of Glamorgan. FCPA (HKICPA), FCCA, Certified Internal Auditor. Fee HK$120k per year, three-year appointment.

n/a (appointed after FY2026)

Mr. Liao Honghao (廖洪浩) — resigned

Former INED; chaired nomination committee

66

2 Mar 2018 to 17 Aug 2026

Marketing general manager at a PRC publishing company. 30+ years in strategic planning and promotion. Meizhou Radio and TV University.

102

Directors' Remuneration

FeatureDetail

Board size / independence

5 directors: 2 executive and 3 INEDs (60% independent)

Chair / CEO separation

No formal chairman or CEO is named. The FY2026 AR describes Mr. Liao Honghao as "executive director and chairman" in the nomination committee section, which is inconsistent with his INED status. This is likely a drafting error and is a governance-quality flag.

Audit committee

Wong Chi Kan (chair), Lao In Iam, Liao Honghao (replaced by Ms. Wong Mei Yin from 17 Aug 2026). Met 3 times in FY2026 with full attendance.

Remuneration committee

Wong Chi Kan (chair), Liao Honghao (replaced by Ms. Wong Mei Yin), Yu Xiao. Met 3 times.

Nomination committee

Liao Honghao (chair until 17 Aug 2026), Wong Chi Kan, Lao In Iam. The current chair after Mr. Met 3 times.

Board meetings

6 in FY2026, with 100% attendance by all directors.

Internal audit

No internal audit function. An external internal-control consultant performs an annual review. The framework references COSO 2013.

Gender diversity

3 of 5 directors are women after August 2026 (Yu Xiao, Lao In Iam, Wong Mei Yin).

Retirement by rotation (2026 AGM)

Chen Jian and Wong Chi Kan, plus Ms. Wong Mei Yin, who was appointed to fill a casual vacancy.

Board & Management Changes

DateChangeContext

Around Sep–Oct 2023

Ms. Lau Wing Yu (劉詠愉) ceases as executive director; Mr. Chen Jian joins as executive director and compliance officer (3 Oct 2023)

Coincides with the rebranding to WMHW

25 Apr 2024

Auditor change from 開元信德 to Infinity CPA (致寶信勤)

Fee disagreement for FY2024 audit

17 Aug 2026

Mr. Liao Honghao resigns as INED; Ms. Wong Mei Yin appointed

Adds governance and internal-audit expertise to the board

Major Shareholders

HolderInterest% of issued sharesSource

Ms. Yu Xiao (executive director)

780,000 (shown as personal interest and underlying shares)

0.26%

FY2026 AR

Mr. Liao Honghao (former INED)

780,0000.26%

FY2026 AR

Ms. Lao In Iam (INED)

780,0000.26%

FY2026 AR

Substantial shareholders (5% or more)

None disclosed in the SFO s.336 register

—

FY2026 AR

Institutional holders (top 10)

Not publicly disclosed. No institutional holders identified.

——

Total insider ownership

About 0.78% (2,340,000 shares or underlying shares) at 31 Mar 2026

0.78%

FY2026 AR

Competitive Landscape

Key Competitors

Company (ticker)Segment overlapLatest revenuePositioning vs. Ju Fu Tang

Kwong Luen Engineering Holdings (1413)

HK civil engineering

HK$618.2M, FY to Mar 2024; gross margin 5.6%; profit before tax HK$21.2M

About 16x larger; profitable at operating level

WLS Holdings / 滙隆控股 (GEM)

HK scaffolding and fitting-out (also an investee)

About HK$76M revenue and HK$39.5M profit before tax for 6 months to 31 Oct 2025 (as cited in the FY2026 AR)

Peer and portfolio holding

Sang Hing Holdings (International) (1472)

HK civil engineering (site formation, roads and drainage)

—

Larger, comparable work type

Kingland Group Holdings (listed as a peer by TipRanks)

HK construction subcontracting

—

Similar micro-cap peer

Build King Holdings (240)

HK civil engineering main contractor

—

Tier-1 contractor; potential customer and competitor

Asia Allied Infrastructure / Chun Wo (711)

HK civil engineering

—

Tier-1 contractor

Chinney Alliance / Chinney Kin Wing (385)

HK foundations and civil works

—

Larger specialist

Kwan On Holdings (1559)

HK civil engineering subcontracting

—

Comparable subcontractor

Unlisted HK subcontractors (various)

Roads, drainage, site formation, fit-out

—

Price competition in tenders

“—” = not publicly disclosed.

Peer Comparison FY2026

MetricJu Fu Tang (FY2026)Kwong Luen (FY2024)WLS Holdings (6 months to Oct 2025)Sang Hing (FY2023)

Revenue (HKD Mn)

37.6618.2

about 76 (half-year)

—

Revenue growth

+3.7%——

Civil revenue about -24% (FY2023)

Gross margin

2.7%5.6%—

Declined (FY2023)

Pre-tax result (HKD Mn)

23.3 (investment-driven)

21.2

about 39.5 (half-year)

about -9 (net loss)

R&D intensity

0%

Not disclosed (assumed nil)

——

“—” = not publicly disclosed.

Company Snapshot

$4.8M

Revenue

23

Employees

2015

Founded

P.O. Box, Cayman Islands

Headquarters

SWOT Analysis

Strengths

  • Balance sheet repair. Net assets rose from HK$27.2M to HK$50.5M and the current ratio from 1.5x to 2.2x in FY2026 (FY2026 AR).
  • Low net debt. Net debt to equity improved from 36.3% to 5.4%. Cash rose more than fourfold to HK$9.3M (FY2026 AR note 5).
  • Durable client relationships. Most of the top five customers have worked with the Group for more than 10 years (Directors' Report).
  • Visible order book. 13 contracts with total value of HK$394.2M, plus HK$32.8M of remaining obligations due within one year (MD&A; note 8).
  • Safety record. Zero work-related fatalities and zero lost days due to injury in FY2025 and FY2026 (ESG report).
  • Tax shield. Unrecognised tax losses of HK$81.0M can shelter future profits (note 14).

Weaknesses

  • Earnings quality. HK$27.4M of FY2026 profit came from fair-value gains, exceeding the entire HK$23.3M net profit (note 11).
  • Core margin. Gross margin of 2.7% with gross profit of HK$1.0M, against administrative costs of HK$8.5M (income statement).
  • Concentration. The largest customer is 85% of revenue and the top five are 100%. The largest supplier and subcontractor each account for 58% (Directors' Report).
  • Receivable quality. The trade receivable loss allowance equals 64% of the gross balance (HK$21.1M of HK$33.0M). One customer more than two years overdue is fully impaired (note 6).
  • Overdue debt. The HK$12M 6% bond has been past maturity since 2 December 2022, with HK$3.7M of interest payable (notes 25 and 27).
  • Thin governance infrastructure. There is no internal audit function and no named chairman or CEO. The annual report contains inconsistent role descriptions (corporate governance report).

Opportunities

  • Public works pipeline. Average government capital works of about HK$120bn per year to 2030–31 (company-cited Budget data).
  • GBA health-tech access. HK Drug and Device Connect, the "1+" mechanism and a new HK medicines regulator could lower barriers to entry (Chairman's Statement).
  • Health-tech scale-up. The segment produced HK$2.1M of revenue in its first year with near break-even segment results (note 9).
  • Equity capacity. A 20% general issue mandate and 30.2M-share option mandate could fund the pivot (AGM circular; note 29).
  • Portfolio monetisation. HK$51.4M of liquid listed equities could be crystallised to retire the bond and fund growth (note 23).
  • Asset-light platform. No PPE and a small headcount (23) keep fixed costs low, so incremental revenue could carry high operating leverage (notes 18; ESG).

Threats

  • Market reversal. A 5% move in investee prices changes pre-tax profit by about HK$2.57M (note 6 sensitivity). The 滙隆 position already fell 74% in FY2026.
  • Customer loss. Losing "Customer A" would remove about 85% of revenue (note 9).
  • Litigation. A HK$3.0M flooding claim was received on 28 May 2026 with no provision made (note 33).
  • Creditor action. The bondholder could enforce the overdue HK$12M bond (note 27).
  • Construction cost inflation. Rising material and labour costs could not be fully passed through in FY2026 (MD&A).
  • Dilution. Option and issue mandates, plus a history of a 2-for-1 rights issue in 2021 and a placing in 2020, point to recurring equity raises (2021 announcement).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
Apr–May 2025Monthly returns filed; no change in share capitalRoutine
–FY2025 results: revenue HK$36.2M (+3.0%), net loss HK$5.90M (narrowed 66%)Continued losses; single civil segment
10 Jun 2025Proposed name change to Ju Fu Tang Biotech Holdings Co., LtdSignals pivot to health care / wellness
Jul 2025FY2025 annual report publishedStatutory
21–22 Aug 2025EGM notice and circular for the name change and 2025 Share Option SchemeGovernance
8 Sep 2025EGM passes name change and new option schemeEnables rebrand and dilution capacity
11 Sep 2025Name change effective (Cayman certificate)Legal rebrand complete
25 Sep 2025AGM poll results announcedRoutine
6 Oct 2025Monthly return to 30 Sep 2025Routine
10 Nov 2025Board meeting notice for interim resultsRoutine
24 Nov 2025Positive profit alert: about HK$21M first-half profit from about HK$23M unrealised fair-value gains on listed investmentsFirst profit swing; investment-driven
28 Nov 2025Interim results (6 months to 30 Sep 2025): revenue HK$17.31M (-33.4%), profit HK$21.44M, EPS 7.1 centsConfirms investment-led profitability
3 Dec 2025Announcement of stock short-name changeRebrand
8 Dec 2025Trading under "JU FU TANG BIOT" beginsMarket-facing rebrand
FY2026 (date not disclosed)Medical-device sales start via Anjulai Biotechnology (Shenzhen)First non-construction revenue
FY2026 (date not disclosed)Office property sold to related party for HK$2.92MLiquidity; related-party transaction
2 Apr, 5 May, 1 Jun 2026Monthly returnsRoutine
28 May 2026Legal claim of about HK$3.0M against subsidiary 聯興 over a June 2020 flooding incidentContingent liability; no provision made
10 Jun 2026Board meeting notice for FY2026 resultsRoutine
22 Jun 2026Positive profit alert: about HK$23M profit driven by about HK$27M fair-value gains and cost controlPre-announcement
30 Jun 2026FY2026 results: revenue HK$37.56M (+3.7%), profit HK$23.32M, 13 contracts (HK$394.2M) on handKey annual print
May–Jul 2026Share price falls from about HK$0.243 (15 May) to about HK$0.11 (early July) despite the profit announcementMarket scepticism; liquidity
6 Jul 2026Monthly return to 30 Jun 2026Routine
31 Jul 2026FY2026 Annual Report, ESG report and AGM circular (general issue and repurchase mandates, re-elections)Statutory; first climate-aligned disclosure
17 Aug 2026Liao Honghao resigns as INED; Ms. Wong Mei Yin appointedBoard refresh with governance expertise
21 Aug 2026Supplemental AGM circular adds resolution to re-elect Ms. WongGovernance
10 Sep 2026Approval of mandates
22 Sep 2026Share closes at HK$0.09 (-10% on the day)Near multi-year low; market cap about HK$27M
6 Oct 2026Monthly return to 30 Sep 2026: authorised 500M shares, par HK$0.16, unchangedNo new issuance
Upcoming (around Nov 2026)Interim results for 6 months to 30 Sep 2026Next catalyst

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

2 charts
Revenue by Segment: Total revenue rose from HKD 35.1 Mn in FY2024 to HKD 37.6 Mn in FY2026.
Ju Fu Tang Biotech Holdings Co., Ltd — Revenue by Segment
Series (HKD Mn)FY2024FY2025FY2026
Total revenue35.136.237.6
Civil engineering, decoration & renovation35.136.235.4
Health technology (medical devices)002.1

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. FY2026 Annual Report (Chinese), Ju Fu Tang Biotech Holdings Co., Ltd, published 31 Jul 2026 (pdf.dfcfw.com)
  2. FY2026 Annual Results Announcement, 30 Jun 2026 (pdf.dfcfw.com)
  3. Positive Profit Alert, 22 Jun 2026 (pdf.dfcfw.com)
  4. Board Meeting Notice, 10 Jun 2026 (static.cninfo.com.cn)
  5. AGM Circular, 31 Jul 2026 (pdf.dfcfw.com)
  6. Supplemental AGM Circular (re-election of Ms. Wong Mei Yin), 21 Aug 2026 (pdf.dfcfw.com)
  7. Monthly Return to 30 Sep 2026 (pdf.dfcfw.com)
  8. HKEX Trading Arrangement Notice — change of company name (effective 8 Dec 2025) (hkex.com.hk)
  9. Proposed change of company name to Ju Fu Tang, 10 Jun 2025 (hkexnews.hk)
  10. EGM Notice, 21 Aug 2025 (hkexnews.hk)
  11. Name change and stock short name (WMHW), 6 Nov 2023: and: www1.hkexnews.hk · www1.hkexnews.hk
  12. Proposed change of name to WMHW, 4 Aug 2023 (www1.hkexnews.hk)
  13. EGM poll results, 22 Sep 2023 (www1.hkexnews.hk)
  14. Change of HK branch share registrar, Nov 2022 (www1.hkexnews.hk)
  15. Proposed share consolidation and rights issue, 2 Aug 2021 (www1.hkexnews.hk)
  16. IPO allotment results, 11 Apr 2016 (hkexnews.hk)
  17. 2020 Interim Results (Chinese) (www1.hkexnews.hk)
  18. Interim results H1 FY2026 coverage (Tiger Brokers / TTM), 28 Nov 2025 (www-web.itiger.com)
  19. Positive profit alert H1 FY2026 coverage, 24 Nov 2025 (www-web.itiger.com)
  20. Name-change coverage, 3 Dec 2025: and: www-web.itiger.com · www-web.itiger.com
  21. FY2026 results summary (Webull / PUBT), 30 Jun 2026 (webull.hk)
  22. FY2025 results summary (Simply Wall St via Tiger) (itiger.com)
  23. etnet company information and announcements list: and: etnet.com.hk · etnet.com.hk
  24. Lixinger quote and announcements list (lixinger.com)
  25. GrowthInvesting quote (22 Sep 2026) (growthinvesting.net)
  26. TipRanks income statement and revenue history (aggregator): and: tipranks.com · tipranks.com
  27. Kwong Luen Engineering FY2024 annual results (peer) (www1.hkexnews.hk)
  28. Sang Hing Holdings FY2023 profit warning (peer) (www1.hkexnews.hk)

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.